Nebenwirkungen · Sitagliptin / Metformin hydrochloride Sun
Sitagliptin/Metformin hydrochloride SUN 50 mg/850 mg film-coated tablets Sitagliptin/Metformin hydrochloride SUN 50 mg/1 000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-149451 · Präparat HOS-100052
TECOS Cardiovascular Safety Study The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) included 7332 patients treated with sitagliptin, 100 mg daily (or 50 mg daily if the baseline eGFR was ≥ 30 and < 50 mL/min/1.73 m2), and 7339 patients treated with placebo in the intention-to-treat population. Both treatments were added to usual care targeting regional standards for HbA1c and CV risk factors. The overall incidence of serious adverse events in patients receiving sitagliptin was similar to that in patients receiving placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-06T12:11:00Z · SHA-256 fd7e3c6c3895b7e664b95bd3e0199493082d8eb279c262d7cecdfbfc68d7c194 · Passage 59936e31beb4ee3bd9c8119cf6fc7ffa9574705fc6e8e736326606fce95b9982 · Zeichen 6059–6607 im Abschnitt